Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 3

Sponsor Class

NIH 3OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Sarcoma 1Myeloid 1CNS 1

Conditions

Leukemia, Myeloid, Acute 2Sinonasal undifferentiated carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Esthesioneuroblastoma, Olfactory 1Chondrosarcoma 1

Interventions

Specimen Handling 184Magnetic Resonance Spectroscopy 139Biopsy 102Immunoglobulin G 38Disulfides 38Cisplatin 37Nivolumab 36Platinum 35Paclitaxel 351,2-diaminocyclohexaneplatinum II citrate 35Radiation 34Cyclophosphamide 34Carboplatin 33Taxes 32Radiotherapy 28X-Rays 27pembrolizumab 26Doxorubicin 25Bevacizumab 24olaparib 22atezolizumab 21Gemcitabine 19Vincristine 18Prednisone 17Etoposide 17Leucovorin 16Cytarabine 16fludarabine 15durvalumab 15Phantoms, Imaging 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × enasidenib × 30 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

NCT06672146 2026-06-02

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
93 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡